examined the effect of DEB-TACE on cellular immune function and regulatory T cells in patients with HCC and found that DEB-TACE can stimulate the cytokine spectrum and increase CD4+ and CD8+ T cells in PBMCs of HCC patients while reducing the Treg cell population (30). Here, CD8A is linked to hepatocellular carcinoma.